Three killed in DSM plant explosion

Dutch life science company DSM reported this week that on Tuesday
three people were killed following an explosion at its Melamine
Plant 2 in Geleen, the Netherlands.

Dutch life science company DSM reported this week that on Tuesday three people were killed following an explosion at its Melamine Plant 2 in Geleen, the Netherlands.

The explosion occured during work on a gas-fired reactor and although initially the temperature in the plants furnace stopped rescue workers from recovering the bodies, the company reported yesterday that the temperature was sufficiently cool for the emergency services to enter the plant.

In a statement Peter Elverding, chairman of the DSM managing board offered his condolences to the family, friends and colleagues of the victims stating that, 'we will do everything we can to help and support the families of the victims.'

A full investigation by the relevant authorities into the causes of the fatal incident has now been launched. Elverding added :'DSM will cooperate fully with this investigation into the exact circumstances surrounding the incident and we will publish further details as soon as we have them. »

The victims are a DSM employee and two contractor employees who were working in the plant. Two other people who were hurt in the explosion were allowed home after receiving treatment from the DSM medical department.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars